



**In the Claims**

1. (Withdrawn) A polymeric composition for coating an implantable device comprising a polysulfone (A) and an elastomeric polymer (B).
2. (Withdrawn) The polymeric composition of claim 1 wherein the elastomeric polymer is selected from the group consisting of polyacrylate with long side chain, polymethacrylate with long side chain, polyisobutylene, polyhexafluoropentene, polysiloxane, and a combination thereof.
3. (Withdrawn) The polymeric composition of claim 1 wherein the polysulfone and the elastomeric polymer form a conjugate.
4. (Withdrawn) The polymeric composition of claim 1 wherein the polysulfone and the elastomeric polymer form a polymer blend.
5. (Withdrawn) The polymeric composition of claim 3 wherein the conjugate comprises a copolymer that comprises at least one block of a polysulfone polymer (A) and at least one block of an elastomeric polymer (B) in a general formula selected from AB, ABA or BAB.
6. (Withdrawn) The polymeric composition of claim 5 wherein the block copolymer is selected from the group consisting of





wherein R<sub>1</sub> is selected from the group consisting of C1 to C10 alkyl, C2, C4 and C6 hydroxyalkyl, C1 to C6 fluoroalkyl, phenyl, substituted phenyl, polyethylene glycol, polyalkylene oxide, ethylene oxide and propylene oxide;

wherein R<sub>2</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub> and R<sub>8</sub> are independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C2, C4 and C6 hydroxyalkyl, C1 to C6 fluoroalkyl, phenyl, substituted phenyl, carboxyl, amido, ester groups bearing a polyethylene glycol, and polyalkylene oxide;

wherein R<sub>3</sub> is selected from the group consisting of hydrogen, alkyl, cycloalkyl, phenyl, carboxyl, halo, amino, hydroxyl, amido, sulfido, and polyalkylene oxide;

wherein R<sub>6</sub> is a perfluoroalkyl group;

wherein R<sub>9</sub> and R<sub>10</sub> are independently selected from the group consisting of H, CH<sub>3</sub>, F and CF<sub>3</sub>; and

wherein n and m are independently positive integers.

7. (Withdrawn) The composition of claim 5 wherein R<sub>1</sub> is butyl, isobutyl or isopropyl;

wherein R<sub>2</sub> is hydrogen or methyl;

wherein R<sub>3</sub> is hydrogen, halo, or methyl;

wherein R<sub>4</sub> and R<sub>5</sub> are independently hydrogen, methyl, ethyl, isopropyl, butyl, isobutyl, or phenyl;

wherein R<sub>6</sub> is F, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, CF<sub>2</sub>CF<sub>2</sub>CF<sub>3</sub>, perfluoroisopropyl, perfluorobutyl or perfluoroisobutyl; and

wherein R<sub>7</sub> and R<sub>8</sub> are independently methyl, ethyl, propyl, isopropyl, butyl, or isobutyl group.

8. (Withdrawn) The composition of claim 6 wherein R<sub>1</sub> is butyl;

wherein R<sub>2</sub> is methyl;

wherein R<sub>3</sub> is hydrogen;

wherein R<sub>4</sub> and R<sub>5</sub> are methyl groups;

wherein R<sub>6</sub> is CF<sub>3</sub>;

wherein R<sub>7</sub> and R<sub>8</sub> are methyl group; and

wherein R<sub>9</sub> and R<sub>10</sub> are methyl groups.

9. (Withdrawn) The coating composition of any of claims 1-8, further comprising a bioactive agent.

10. (Withdrawn) The coating composition of claim 9, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, sirolimus, sirolimus derivatives, paclitaxel, taxoids, estradiol, steroidal anti-inflammatory agents, antibiotics, nitric oxide donors, super oxide dismutases, super oxide dismutase mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), and a combination thereof.

11. (Currently amended) An implantable device comprising a coating, which comprises a polymeric composition comprising a polysulfone (A) and an elastomeric polymer (B), wherein the elastomeric polymer is selected from the group consisting of polyisobutylene, polyperfluoroalkylene, polyhexafluoropentene, polysiloxane, natural rubber, nylon, ~~polymers and copolymers of acrylates or methacrylates~~ poly(lauryl methacrylate), and a combination thereof.

12. (Previously presented) The implantable device of claim 11, wherein the device is a stent.

13. (Previously presented) The implantable device of claim 12, wherein the coating further comprises a bioactive agent.

14. (Previously presented) The implantable device of claim 13 wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, paclitaxel, taxoids, estradiol, steroidal anti-inflammatory agents, antibiotics, nitric oxide donors, super oxide dismutases, super oxide dismutase mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), and a combination thereof.

15. (Withdrawn) A method of forming an implantable device, comprising forming a coating on the implantable device comprising a composition as defined in any of claims 1-8.

16. (Withdrawn) The method of claim 15 wherein the implantable device is a stent.

17. (Withdrawn) A method of forming a DES, comprising forming a coating on the DES comprising the composition of claim 9.

18. (Withdrawn) The method of claim 17 wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, paclitaxel, taxoids, estradiol, steroidal anti-inflammatory agents, antibiotics, nitric oxide donors, super oxide dismutases, super oxide dismutase mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), and a combination thereof.

19. (Withdrawn) A method of treating a disorder in a patient comprising implanting in the patient the implantable device of claim 11.

20. (Withdrawn) The method of claim 19 wherein the implantable device is a stent.

21. (Withdrawn) A method of treating a disorder in a patient comprising implanting in the patient the DES of claim 13.

22. (Withdrawn) The method of claim 21 wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, paclitaxel, taxoids, estradiol, steroidal anti-inflammatory agents, antibiotics, nitric oxide donors, super oxide dismutases, super oxide dismutase mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), and a combination thereof.

23. (Withdrawn) The method of claim 19 wherein the disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, vulnerable plaques and a combination thereof, and a combination thereof.


24. (Withdrawn) The method of claim 20 wherein the disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, vulnerable plaques and a combination thereof, and a combination thereof.

25. (Withdrawn) The method of claim 22 wherein the disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, vulnerable plaques and a combination thereof, and a combination thereof.

26. (Withdrawn) The method of claim 23 wherein the disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, vulnerable plaques and a combination thereof, and a combination thereof.

27. (Withdrawn) A polymeric conjugate comprises a copolymer that comprises at least one block of a polysulfone polymer (A) and at least one block of an elastomeric polymer (B) in a general formula selected from AB, ABA or BAB.

28. (Withdrawn) The polymeric conjugate of claim 27 wherein the block copolymer is selected from the group consisting of



wherein R<sub>1</sub> is selected from the group consisting of C1 to C10 alkyl, C2, C4 and C6 hydroxyalkyl, C1 to C6 fluoroalkyl, phenyl, substituted phenyl, polyethylene glycol, polyalkylene oxide, ethylene oxide and propylene oxide;

wherein R<sub>2</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub> and R<sub>8</sub> are independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C2, C4 and C6 hydroxyalkyl, C1 to C6 fluoroalkyl, phenyl, substituted phenyl, carboxyl, amido, ester groups bearing a polyethylene glycol, and polyalkylene oxide;

wherein R<sub>3</sub> is selected from the group consisting of hydrogen, alkyl, cycloalkyl, phenyl, carboxyl, halo, amino, hydroxyl, amido, sulfido, and polyalkylene oxide;

wherein R<sub>6</sub> is a perfluoroalkyl group;

wherein R<sub>9</sub> and R<sub>10</sub> are independently selected from the group consisting of H, CH<sub>3</sub>, F and CF<sub>3</sub>; and

wherein n and m are independently positive integers.

29. (Withdrawn) The polymeric conjugate of claim 28 wherein R<sub>1</sub> is butyl, isobutyl or isopropyl;

wherein R<sub>2</sub> is hydrogen or methyl;

wherein R<sub>3</sub> is hydrogen, halo, or methyl;

wherein R<sub>4</sub> and R<sub>5</sub> are independently hydrogen, methyl, ethyl, isopropyl, butyl, isobutyl, or phenyl;

wherein R<sub>6</sub> is F, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, CF<sub>2</sub>CF<sub>2</sub>CF<sub>3</sub>, perfluoroisopropyl, perfluorobutyl or perfluoroisobutyl; and

wherein R<sub>7</sub> and R<sub>8</sub> are independently methyl, ethyl, propyl, isopropyl, butyl, or isobutyl group.

30. (Withdrawn) The polymeric conjugate of claim 28 wherein R<sub>1</sub> is butyl;

wherein R<sub>2</sub> is methyl;

wherein R<sub>3</sub> is hydrogen;

wherein R<sub>4</sub> and R<sub>5</sub> are methyl groups;

wherein R<sub>6</sub> is CF<sub>3</sub>;

wherein R<sub>7</sub> and R<sub>8</sub> are methyl group; and

wherein R<sub>9</sub> and R<sub>10</sub> are methyl groups.

31. (Canceled).


32. (Previously presented) The implantable device of claim 11, wherein the polysulfone and the elastomeric polymer form a conjugate.

33. (Previously presented) The implantable device of claim 11, wherein the polysulfone and the elastomeric polymer form a polymer blend.

34. (Previously presented) The implantable device of claim 32, wherein the conjugate comprises a copolymer that comprises at least one block of a polysulfone polymer (A) and at

least one block of an elastomeric polymer (B) in a general formula selected from AB, ABA or BAB.

35. (Currently amended) The implantable device of claim 34, wherein the block copolymer is selected from the group consisting of




wherein  $\text{R}_1$  is selected from the group consisting of C1 to C10 alkyl, C2, C4 and C6 hydroxyalkyl, C1 to C6 fluoroalkyl, phenyl, substituted phenyl, polyethylene glycol, polyalkylene oxide, ethylene oxide and propylene oxide;

wherein  $\text{R}_2$ ,  $\text{R}_4$ ,  $\text{R}_5$ ,  $\text{R}_7$  and  $\text{R}_8$  are independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C2, C4 and C6 hydroxyalkyl, C1 to C6 fluoroalkyl, phenyl, substituted phenyl, carboxyl, amido, ester groups bearing a polyethylene glycol, and polyalkylene oxide;


wherein  $\text{R}_3$  is selected from the group consisting of hydrogen, alkyl, cycloalkyl, phenyl, carboxyl, halo, amino, hydroxyl, amido, sulfido, and polyalkylene oxide;

wherein  $\text{R}_6$  is a perfluoroalkyl group;



wherein  $\text{R}_4$ ,  $\text{R}_5$ , and  $\text{R}_6$  are selected such that the block and the





wherein n and m are independently positive integers.

36. (Currently amended) The implantable device of claim 35, wherein R<sub>1</sub> is butyl, isobutyl or isopropyl;

wherein R<sub>2</sub> is hydrogen or methyl;

wherein R<sub>3</sub> is hydrogen, halo, or methyl;

wherein R<sub>4</sub> and R<sub>5</sub> are independently hydrogen, methyl, ethyl, isopropyl, butyl, isobutyl, or phenyl;

wherein R<sub>6</sub> is F, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, CF<sub>2</sub>CF<sub>2</sub>CF<sub>3</sub>, perfluoroisopropyl, perfluorobutyl or perfluoroisobutyl; and

wherein R<sub>7</sub> and R<sub>8</sub> are independently methyl, ethyl, propyl, isopropyl, butyl, or isobutyl group.

37. (Currently amended) The implantable device of claim 35, wherein R<sub>1</sub> is butyl;

wherein R<sub>2</sub> is methyl;

wherein R<sub>3</sub> is hydrogen;

wherein R<sub>4</sub> and/or R<sub>5</sub> are methyl groups;

wherein R<sub>6</sub> is CF<sub>3</sub>; and

wherein R<sub>7</sub> and R<sub>8</sub> are methyl group

38. (Canceled)

39. (Canceled)